CD5 and non-Hodgkin lymphoma: Targeting deletion of miR-15a~16 in mice led to the development of a spectrum of diseases resembling CLL-associated lymphoproliferation in humans, including CLL, CD5+ monoclonal B-cell lymphocytosis, and CD5− non-Hodgkin's lymphomas [644].